Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. (Q46001455)

18 December 2017

title

Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. (English)

1 reference

18 December 2017

1 reference

1 reference

3

Marie-Claude Boily

1 reference

18 December 2017

author name string

Nicolas Van de Velde

series ordinal

1

1 reference

18 December 2017

Marc Brisson

series ordinal

2

1 reference

18 December 2017

language of work or name

English

0 references

publication date

2 June 2010

1 reference

18 December 2017

published in

Vaccine

1 reference

18 December 2017

volume

28

1 reference

18 December 2017

issue

33

1 reference

18 December 2017

page(s)

5473-5484

1 reference

18 December 2017

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Benefits and costs of using HPV testing to screen for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Economic evaluation of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Economic evaluation of human papillomavirus vaccination in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Structural differences among cost-effectiveness models of human papillomavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Modeling cervical cancer prevention in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Stability over time of serum antibody levels to human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

The predicted effect of changes in cervical screening practice in the UK: results from a modelling study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Epidemiological models for sexually transmitted diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

The effect of pair formation and variable infectivity on the spread of an infection without recovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Mind the gap: the role of time between sex with two consecutive partners on the transmission dynamics of gonorrhea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

A metapopulation modelling framework for gonorrhoea and other sexually transmitted infections in heterosexual populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Classification of papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Health and economic implications of HPV vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

More realistic models of sexually transmitted disease transmission dynamics: sexual partnership networks, pair models, and moment closure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Vaccination and the evolutionary ecology of human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Economic evaluation of vaccination programs: the impact of herd-immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

Sexual Contact Patterns between Men and Women and the Spread of HIV-1 in Urban Centres in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.056

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.05.056

1 reference

18 December 2017

PubMed ID

20573580

1 reference

18 December 2017